ACT 1

Drug Profile

ACT 1

Alternative Names: ACT-1; Connexin-43 mimic - FirstString Research; Gap junction peptide - FirstString Research; Granexin Gel; Wound-healing peptide gel - FirstString Research

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator FirstString Research; Medical University of South Carolina
  • Class Peptide fragments
  • Mechanism of Action Gap junction modulators; Tight junction protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer; Leg ulcer; Scars
  • Preclinical Age-related macular degeneration; Corneal injuries; Fibrosis
  • No development reported Spinal cord injuries

Most Recent Events

  • 27 Jul 2016 The US FDA approves phase III development programme for Diabetic foot ulcers and Leg ulcers in USA
  • 27 Jul 2016 RELIEF THERAPEUTICS plans phase III trials in Leg ulcers in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (Topical, Patch)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top